Publications by authors named "Holly B Krasa"

19Publications

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

Nephrol Dial Transplant 2016 11 17;31(11):1887-1894. Epub 2015 Dec 17.

Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, 200 First St. SW Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfv422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367945PMC
November 2016

Prevalence of autosomal dominant polycystic kidney disease in the European Union.

Nephrol Dial Transplant 2017 Aug;32(8):1356-1363

Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfw240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837385PMC
August 2017

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Kidney Int 2013 Dec 31;84(6):1278-86. Epub 2013 Jul 31.

Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ki.2013.285DOI Listing
December 2013

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

N Engl J Med 2012 Dec 3;367(25):2407-18. Epub 2012 Nov 3.

Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1205511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760207PMC
December 2012

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Kidney Int 2011 Aug 4;80(3):295-301. Epub 2011 May 4.

Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ki.2011.119DOI Listing
August 2011

Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.

Am J Health Syst Pharm 2011 Feb;68(4):328-33

Health Economics and Outcomes Research, Boston Healthcare Associates, Inc., MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp100217DOI Listing
February 2011

Effects of tolvaptan on dyspnoea relief from the EVEREST trials.

Eur Heart J 2009 Sep 27;30(18):2233-40. Epub 2009 Jun 27.

Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehp253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742783PMC
September 2009